Clinical trial · no report yet · Phase 1
NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- NCT04970901 ↗
- Active not recruiting
- ADC Therapeutics S.A.
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| Podcasts | 7 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- B-Cell Non-Hodgkin Lymphoma; Relapsed B-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Loncastuximab Tesirine; Polatuzumab Vedotin; Glofitamab; Mosunetuzumab; Obinutuzumab
- Arms
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C) · Experimental
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Glofitamab (Arm E) · Experimental
- Part 1 (Dose Escalation): Loncastuximab Tesirine + Mosunetuzumab (Arm F) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Polatuzumab Vedotin (Arm C) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Glofitamab (Arm E) · Experimental
- Part 2 (Dose Expansion): Loncastuximab Tesirine + Mosunetuzumab (Arm F) · Experimental
- Enrollment
- 154
- Primary outcomes
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption
- Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Measurements
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs
- Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
- Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements
- Sponsor
- ADC Therapeutics S.A.
- Start
- Jun 17, 2022
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04970901 · updated Jul 17, 2026